New-onset urticaria

Official reprint from UpToDate® www.uptodate.com

©2023 UpToDate®

New-onset urticaria
Author: Riccardo Asero, MD
Section Editors: Sarbjit Saini, MD, Jeffrey Callen, MD, FACP, FAAD
Deputy Editor: Anna M Feldweg, MD

Contributor Disclosures

All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Oct 2023. | This topic last updated: Jun 27, 2023.

INTRODUCTION

Urticaria, or hives (sometimes referred to as welts or wheals), is a common disorder, with a

lifetime prevalence of approximately 20 percent in the general population [1]. A typical
urticarial lesion is an intensely pruritic, erythematous plaque ( picture 1). Urticaria is
sometimes accompanied by angioedema, which is swelling deeper in the skin. A presumptive
trigger, such as a drug, food ingestion, insect sting, or infection, may be identifiable in
patients with new-onset urticaria, although no specific cause is found in many cases,
particularly when the condition persists for weeks or months. (See 'Etiologies' below.)

The epidemiology, clinical manifestations, etiologies, diagnosis, and management of new-

onset urticaria will be reviewed here. Chronic urticaria and isolated angioedema are discussed
separately.

● (See "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis,

and natural history".)

● (See "Chronic spontaneous urticaria: Standard management and patient education".)

● (See "An overview of angioedema: Clinical features, diagnosis, and management".)

- Page 1 of 32 -
New-onset urticaria

CATEGORIZATION OF URTICARIA

Urticaria (with or without angioedema) is commonly categorized by its chronicity:

Acute urticaria — Urticaria is considered acute when it has been present for less than six
weeks.

Chronic urticaria — Urticaria is considered chronic when it is recurrent, with signs and
symptoms recurring most days of the week, for six weeks or longer.

The period of six weeks is somewhat arbitrary and simply represents a timeframe in which
new cases of urticaria usually resolve. More than two-thirds of cases of new-onset urticaria
prove to be self-limited (acute) [2]. The lesions of acute and chronic urticaria are identical in
appearance, so when the problem first develops, it is not possible to differentiate the two
disorders [3].

EPIDEMIOLOGY

Urticaria affects up to 20 percent of the population at some point in their lives and occurs
across the age spectrum [1].

CLINICAL MANIFESTATIONS

Urticarial lesions are circumscribed, raised, erythematous plaques, often with central pallor (
picture 2). Lesions may be round, oval, or serpiginous in shape and vary in size from less
than 1 centimeter to several centimeters in diameter. They are intensely itchy. Pruritus may
disrupt work, school, or sleep. Symptoms often seem most severe at night.

Individual lesions are transient, usually appearing and enlarging over the course of minutes
to hours and then disappearing within 24 hours. Lesions may coalesce as they enlarge (
picture 3A-B). Urticarial lesions are not normally painful and resolve without leaving
residual ecchymotic marks on the skin, unless there is trauma from scratching. If lesions are
long-lasting, painful, or leave residual bruising, the diagnosis of urticarial vasculitis should be
- Page 2 of 32 -
New-onset urticaria

considered. (See 'Differential diagnosis' below.)

Any area of the body may be affected, although areas in which clothing compresses the skin
(eg, under waistbands) or skin rubs together (axillae) are sometimes affected more
dramatically. Typically, compressed areas become more severely affected once the restricting
clothing has been removed.

Angioedema, when associated with urticaria, usually affects the face and lips, extremities,
and/or genitals. Angioedema without urticaria should prompt consideration of other
angioedema disorders, such as drug-induced angioedema (eg, angiotensin-converting
enzyme [ACE] inhibitors), idiopathic angioedema, and hereditary and acquired C1 inhibitor
deficiency. (See "ACE inhibitor-induced angioedema" and "An overview of angioedema:
Pathogenesis and causes".)

PATHOPHYSIOLOGY

Urticaria is mediated by cutaneous mast cells in the superficial dermis. Basophils have also
been identified in lesional biopsies [4]. Mast cells and basophils release multiple mediators
upon activation including histamine (which causes itching) and vasodilatory mediators (which
cause localized swelling in the uppermost layers of the skin). The same process gives rise to
angioedema when mast cells deeper in the dermis and subcutaneous tissues are activated.
(See "Mast cells: Development, identification, and physiologic roles".)

ETIOLOGIES

The potential causes of new-onset urticaria are numerous, although no specific etiology can
be identified in many patients. Acute urticaria is more likely to have an identifiable etiology
compared with chronic urticaria. The different etiologies activate mast cells through various
mechanisms.

Common causes — Common causes of new-onset urticaria include infections; allergic

reactions to medications, foods, or insect stings and bites; reactions to medications that
cause nonallergic mast cell activation (eg, narcotics); and ingestion of nonsteroidal anti-
- Page 3 of 32 -
New-onset urticaria

inflammatory drugs (NSAIDs) ( table 1).

Infections — Viral, bacterial, and parasitic infections are associated with new-onset urticaria.

● Viral and bacterial infections – Acute urticaria may develop during or following a viral
or bacterial infection, particularly in children. Infections are associated with over 80
percent of cases of acute urticaria in some pediatric series [2,5-8]. Immune activation,
involving immune complex formation and/or complement activation, is a proposed
mechanism, although the exact pathogenesis is unclear.

• In one study, common viral illnesses and bacterial infections (eg, urinary tract
infections) were the leading identifiable trigger for acute urticaria in 57 children
between the ages of one and three years who presented to an emergency
department [5]. Many of these children had also received antibiotics, so it was not
clear in these patients if the infection, the drug, or the combination had triggered
urticaria.

• In another study, 88 children presenting to an emergency department with delayed

cutaneous reactions while taking beta-lactam antibiotics were evaluated. Of these, 47
of 88 had urticarial eruptions. All were tested for common childhood viral infections
and then later evaluated for drug allergy with testing followed by drug challenge
(regardless of test results) [9]. Two-thirds had one or more positive viral studies,
demonstrating infections with picornavirus (most common), coronavirus, respiratory
syncytial virus, and several others. When the children were later challenged with the
culprit antibiotic, only 4 had recurrent urticaria. Thus, urticaria was related to the
viral infection or the combination of the viral infection and the antibiotic in most, and
only 4 of 88 had a drug allergy. (See "Penicillin allergy: Delayed hypersensitivity
reactions", section on 'Delayed urticarial eruptions'.)

• Acute urticaria, refractory to antihistamines but responsive to azithromycin, has been

associated with documented Mycoplasma pneumoniae infection in children [10,11].

• Acute urticaria can occur in the prodromic, preicteric phase of hepatitis A or B

infection and less commonly with hepatitis C [12]. Urticaria may be an initial
manifestation of human immunodeficiency virus (HIV) infection [13]. (See "Acute and
- Page 4 of 32 -
New-onset urticaria

early HIV infection: Pathogenesis and epidemiology".)

• Episodes of acute urticaria, as well as of reactivation of chronic spontaneous urticaria

that was in a remission state, have been observed following severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection during the pandemic period both in
children [14] and in adults [15]. In addition, short-lived episodes of acute urticaria
have been recorded following SARS-CoV-2 vaccination both in subjects with prior
chronic urticaria and in normal subjects [16].

● Parasitic infections – Parasitic infections generally cause acute, self-limited urticaria in

association with prominent eosinophilia [17].

• Infections with Ancylostoma, Strongyloides, Filaria, Echinococcus, Trichinella,

Toxocara, Fasciola, Schistosoma mansoni, and Blastocystis hominis have all been
associated with urticaria. Stool examination is probably only indicated in travelers to
endemic areas and in patients with peripheral blood eosinophilia. (See "Approach to
the patient with unexplained eosinophilia".)

• Ingestion of fish contaminated with the parasite Anisakis simplex can also cause
urticaria. Anisakis can be transmitted through the ingestion of sushi [18]. (See
"Seafood allergies: Fish and shellfish", section on 'Anisakis'.)

COVID-19 vaccines and boosters — Urticaria with or without angioedema has been
reported in association with coronavirus disease 2019 (COVID-19) messenger ribonucleic acid
(mRNA) vaccines and boosters, particularly the Moderna mRNA booster. In a study of over
800 patients in two cohorts with newly diagnosed urticaria that had occurred most days of
the week and persisted for weeks to months, 92 and 94 percent of cases were temporally
associated with receiving the Moderna vaccine or booster [19]. Onset of urticaria was
between 8 and 13 days after vaccination. In those patients with subsequent resolution, the
duration of symptoms ranged from two to six months. The author and editors of this topic
have also observed reactivation of chronic urticaria that had been quiescent for years.

IgE-mediated allergic reactions — Immunoglobulin E (IgE)-mediated, type I immediate

allergic reactions often involve urticaria. Urticaria that is caused by an allergic reaction usually
occurs within minutes to two hours of exposure to the culprit allergen. Causes include
- Page 5 of 32 -
New-onset urticaria

medications, foods and food additives, insect stings and bites, latex, and blood products.

Allergic reactions may be limited to the skin or part of a systemic allergic reaction (eg,
anaphylaxis) ( table 2 and table 3). Generalized urticaria or angioedema following
exposure to a potential allergen should be interpreted as a systemic reaction with an
attendant risk of anaphylaxis upon subsequent exposure, and patients should be advised to
avoid the potential cause until further evaluated. (See 'Referral' below.)

● Medications – The antibiotics most frequently implicated in causing IgE-mediated

urticaria include beta-lactams (penicillins and cephalosporins), although antibiotics from
virtually all classes have been reported ( picture 4). (See "Penicillin allergy: Immediate
reactions".)

● Stinging and biting insects – Stinging insects that can cause true urticarial lesions as
part of an allergic reaction include Hymenoptera (eg, bees, wasps, hornets, and
imported fire ants) and Triatoma (eg, kissing bugs).

Bedbugs, fleas, and mites can cause papular urticaria, usually on the lower extremities.
The lesions of papular urticaria resolve over the course of weeks. (See "Bee, yellow
jacket, wasp, and other Hymenoptera stings: Reaction types and acute management"
and "Reactions to bites from kissing bugs (primarily genus Triatoma)" and "Bedbugs".)

● Latex – Occupational, recreational, dental, or surgical exposure to latex may cause

urticaria, angioedema, asthma, or anaphylaxis in susceptible individuals [20]. Everyday
scenarios in which patients may be exposed to significant amounts of latex include
inflation of balloons and use of latex gloves. Penile and vulvar/vaginal urticaria and
angioedema are seen upon exposure to latex condoms, with vulvar/vaginal symptoms
resembling acute vaginitis. (See "Latex allergy: Epidemiology, clinical manifestations,
and diagnosis".)

● Foods and certain food additives – Allergic reactions to foods can cause urticaria,
typically within 30 minutes of ingestion. Milk, eggs, peanuts, tree nuts, soy, and wheat
are the most common foods to cause generalized urticaria in children. In adults, fish,
shellfish, tree nuts, and peanuts are most often implicated [21]. In Mediterranean areas,
the most frequent cause of food-induced urticaria is the peach, due to sensitization to
- Page 6 of 32 -
New-onset urticaria

lipid transfer protein [22]. (See "Clinical manifestations of food allergy: An overview".)

Synthetic additives in commercially prepared foods are believed to be a relatively rare

cause of urticarial reactions. In contrast, certain natural compounds, such as the yellow
food dye annatto and the red dye carmine red, have been well-documented causes of
urticaria and anaphylaxis. Adverse reactions to food additives are discussed in detail
elsewhere. (See "Allergic and asthmatic reactions to food additives".)

● Contact with allergens – Physical contact with a number of agents may result in
urticaria, including plant products and resins, raw fruits and vegetables, or raw seafood.
People employed in food processing can develop contact urticaria from various
exposures [23]. Children sometimes develop urticaria upon contact with animal saliva, if
allergic to those allergens. In contrast, detergents, soaps, and lotions are more likely to
cause contact dermatitis than urticaria. (See "Clinical features and diagnosis of allergic
contact dermatitis" and "Allergic contact dermatitis in children".)

● Urticarial transfusion reactions – Acute urticaria in the setting of transfusion may

arise from several mechanisms, including IgE-mediated allergic reactions, complement-
mediated reactions, and other immunologic events. These reactions are discussed
elsewhere. (See "Immunologic transfusion reactions".)

Direct mast cell activation — Certain drugs and plants can cause urticaria due to mast cell
degranulation through a non-IgE-mediated mechanism. The most frequently implicated are
narcotics, muscle relaxants, vancomycin, and radiocontrast media. Nettle plants are examples
of plants that cause direct mast cell activation. Some years ago "pseudoallergens" contained
in certain foods were considered as a possible co-factor in patients with chronic urticaria, and
this concept appeared in the European Academy of Allergy and Clinical Immunology (EAACI)
Guidelines for a while, but the lack of any convincing evidence has led to the exclusion of this
hypothesis in the most recent, revised versions of this document [24]. In these cases, urticaria
may develop variably within minutes to some hours after contact; in the case of drugs, this
may sometimes depend on the route of administration of a drug (eg, oral versus
intramuscular/intravenous). The wheal-and-flare response to stinging nettle is practically
immediate (a few seconds).

- Page 7 of 32 -
New-onset urticaria
● Narcotics – Opiate analgesics, such as morphine and codeine, cause direct mast cell
activation. Dextromethorphan, an opiate derivative ingredient in cough suppressant
syrups, can also cause urticaria [25].

● Muscle relaxants – Anesthetic muscle relaxants, including atracurium, vecuronium,

succinylcholine, and curare, may cause urticaria. Muscle relaxants can also cause IgE-
mediated anaphylaxis. Allergic reactions to these medications are reviewed in greater
detail elsewhere. (See "Perioperative anaphylaxis: Clinical manifestations, etiology, and
management".)

● Vancomycin – Vancomycin infusion reaction is seen after rapid vancomycin infusion and
presents as diffuse erythema or flushing, sometimes with accompanying urticaria. The
concomitant use of opiates and vancomycin may increase the likelihood of a reaction.
(See "Vancomycin hypersensitivity".)

● Radiocontrast medium – Radiocontrast agents are associated with urticaria and

angioedema. (See "Diagnosis and treatment of an acute reaction to a radiologic contrast
agent".)

● Stinging nettle – The nettle plant (Urtica dioica), after which the disorder "urticaria" was
named, is a common weed found in Europe, North and South America, and parts of
Africa that causes hives and a stinging sensation immediately following contact with the
skin [26-28]. These symptoms may be due to histamine in the nettle plant itself, in
addition to mediators that cause pain [29].

Nonsteroidal anti-inflammatory drugs — Nonsteroidal anti-inflammatory drugs (NSAIDs),

such as aspirin, ibuprofen, naproxen sodium, and others, can trigger urticaria and/or
angioedema by two distinct mechanisms:

● Pseudoallergic/pharmacologic – NSAIDs cause urticaria in some individuals,

presumably due to underlying abnormalities in arachidonic acid metabolism. This form
of NSAID reaction is called a pseudoallergic reaction because the mechanism is
nonimmunologic. NSAID pseudoallergy can be seen with any agent (eg, aspirin,
ibuprofen) that inhibits the cyclooxygenase 1 (COX-1) enzyme and rarely occurs with
agents that are very weak inhibitors of COX-1. Patients with pseudoallergy usually
- Page 8 of 32 -
New-onset urticaria

tolerate acetaminophen and the selective cyclooxygenase 2 (COX-2) inhibitors.

Pseudoallergic reactions attributed to NSAIDs are discussed in more detail separately.
(See "NSAIDs (including aspirin): Allergic and pseudoallergic reactions", section on
'Pseudoallergic reactions'.)

● Allergic – A specific NSAID can also cause acute urticaria in patients who are allergic to
that one agent. These reactions are presumed to represent true, immunologic allergy.
(See "NSAIDs (including aspirin): Allergic and pseudoallergic reactions", section on
'Allergic reactions (presumed IgE-mediated)'.)

Both allergic and pharmacologic reactions to NSAIDs may occur within minutes after taking
the drug, although pharmacologic reaction may frequently take longer (up to one to two
hours). Both pharmacologic and allergic reactions to NSAIDs can be severe. However, the
management differs. (See "NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
section on 'Management'.)

Scombroid syndrome — The ingestion of poorly preserved fish (tuna in most cases, but
sometimes mackerel or sardines) containing large amounts of histamine may cause acute
symptoms that resemble those of an IgE-mediated allergic reaction characterized by flushing,
urticaria, diarrhea, headache, and sometimes bronchospasm. In this case also, symptoms
may appear from a few minutes up to one to two hours after ingestion depending on the
concentration of histamine in the fish, the quantity ingested, and the association with other
foods. (See "Scombroid (histamine) poisoning".)

Uncommon causes — Uncommon causes of new-onset urticaria include various physical

factors, serum sickness, and hormone-associated disorders.

● Physical stimuli – Physical urticarial syndromes are forms of chronic urticaria that are
triggered by specific physical factors, such as cold exposure, sudden changes in body
temperature, pressure or vibration against the skin, exercise, exposure to sunlight, or
other stimuli. These disorders are reviewed separately. (See "Physical (inducible) forms
of urticaria" and "Cold urticaria".)

● Serum sickness – Serum sickness and serum sickness-like reactions to exogenous

proteins or medications may present with an urticarial rash accompanied by fever,
- Page 9 of 32 -
New-onset urticaria

polyarthralgias, polyarthritis, and/or lymphadenopathy. This typically develops within

one to three weeks after administration of the causative agent. Proteinuria, edema, and
abdominal pain may also be present. These reactions are discussed elsewhere. (See
"Serum sickness and serum sickness-like reactions".)

● Progesterone-associated urticaria – There are rare reports of progesterone-containing

oral contraceptives, hormone replacement therapy, or endogenous progesterone
associated with cyclic urticaria [30,31]. The disorder is sometimes called autoimmune
progesterone dermatitis [32-35]. Lesions usually appear during the second half of the
menstrual cycle and resolve with menstruation.

SYSTEMIC DISORDERS THAT MAY INCLUDE URTICARIA

Uncommonly, urticaria or urticaria-like lesions may be an early feature of a systemic disorder,

including the following:

● Urticarial vasculitis – Urticarial vasculitis should be suspected when individual lesions

are painful, are long-lasting (longer than 24 to 36 hours), appear purpuric or ecchymotic,
or leave residual ecchymosis or hyperpigmentation upon resolution (in the absence of
trauma from scratching) ( picture 5 and picture 6 and picture 7). Vasculitis
should also be suspected in patients with urticaria accompanied by fever, arthralgias,
arthritis, weight changes, bone pain, or lymphadenopathy. Urticarial vasculitis may be a
cutaneous or systemic disease, and it may occur in the setting of another rheumatologic
disorder or rarely, a malignancy. (See "Urticarial vasculitis" and "Cutaneous
manifestations of internal malignancy".)

● Mastocytosis – Mastocytosis and mast cell disorders are rare conditions in which
patients present with apparent allergic reactions and anaphylaxis to a variety of triggers.
Characteristic skin findings are helpful in diagnosis. These disorders are reviewed
separately. (See "Mastocytosis (cutaneous and systemic) in adults: Epidemiology,
pathogenesis, clinical manifestations, and diagnosis".)

● Systemic lupus erythematosus, rheumatoid arthritis, Sjögren's disease, celiac

- Page 10 of 32 -
New-onset urticaria

disease, autoimmune thyroid disease, and other autoimmune diseases – Urticaria

may be a presenting manifestation or occur sporadically over time in patients with
autoimmune conditions [36]. The etiology of this remains unclear but may be due to
direct mast cell activation via complement receptors or due to the generation of
autoantibodies that may result in anaphylactoid degranulation. Screening for these
disorders in the setting of an acute episode of urticaria is not indicated, unless there are
other preceding symptoms that suggest that one of these disorders may be present.

● Cutaneous small vessel vasculitis – Some forms of cutaneous small vessel vasculitis
can appear urticarial during early stages. Urticarial lesions that are persistent in a single
location for >24 hours, have bruising, are painful, or are accompanied by systemic
symptoms (eg, fever) should raise a concern for vasculitis.

• Urticarial vasculitis is a disorder characterized by urticarial lesions with vasculitic

findings on skin biopsy ( picture 6). The disorder may be systemic or limited to the
skin. (See "Urticarial vasculitis".)

• Immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura) is a systemic vasculitis

with a prominent cutaneous component characterized by purpuric lesions,
particularly involving the lower extremities. The skin lesions can be urticarial initially,
although the development of systemic disease with arthralgias, abdominal pain, and
renal involvement should prompt investigation for this condition. (See "IgA vasculitis
(Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Skin
manifestations'.)

• Patients with lupus may also develop urticarial lesions that persist and become
vasculitic. Skin biopsy may show evidence of vasculitis. (See "Overview of cutaneous
lupus erythematosus".)

● Malignancies – Urticaria may also be seen with malignancies, especially

immunoglobulin M (IgM) and sometimes immunoglobulin G (IgG) paraproteinemias.
The etiology is also unclear but may be due to complement-mediated pathways. In
these cases, the urticaria is persistent and becomes chronic. (See "Chronic spontaneous
urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section

- Page 11 of 32 -
New-onset urticaria

on 'Unclear association with malignancy'.)

The urticaria associated with systemic disorders is usually recurrent, persistent, and relatively
difficult to treat, so patients with these disorders typically present with chronic urticaria.
Clinical features that can help distinguish these disorders from uncomplicated chronic
urticaria are reviewed separately. (See "Chronic spontaneous urticaria: Clinical manifestations,
diagnosis, pathogenesis, and natural history", section on 'Differential diagnosis'.)

EVALUATION AND DIAGNOSIS

Urticaria is diagnosed clinically, based upon a detailed history and physical examination
confirming the presence of characteristic skin lesions [37-40].

Clinical history — The clinical history should determine the following:

● Were there other signs and symptoms of a generalized allergic reaction or anaphylaxis?
Patients may fail to report more subtle symptoms unless specifically asked. The clinician
should ask about chest tightness or difficulty breathing, hoarse voice or throat
tightness, nausea, vomiting, crampy abdominal pain, lightheadedness, and other
symptoms of anaphylaxis ( table 2). (See "Anaphylaxis: Emergency treatment".)

● Has the patient had hives previously in the past? Some children develop acute urticaria
repeatedly with infections. Adults may develop urticaria following nonsteroidal anti-
inflammatory drug (NSAID) ingestion but may not recognize the association until it has
occurred several times. Does the patient have other allergic disorders?

● Were there any symptoms or signs to suggest an underlying systemic disorder?

Specifically, has the patient recently had unexplained fever, weight loss, arthralgias,
arthritis, or bone pain [41,42]? Diseases that may include hives as part of the clinical
presentation are reviewed separately. (See 'Systemic disorders that may include
urticaria' above.)

● Is a possible etiology apparent from the patient's history ( table 1)? (See 'Etiologies'
above.)

- Page 12 of 32 -
New-onset urticaria

• Was the patient in his/her usual state of health when the hives appeared or has the
patient been ill recently with viral or bacterial infections? Has the patient experienced
any recent health events, such as musculoskeletal injuries for which he/she was
taking NSAIDs or new diagnoses requiring unfamiliar medications or treatments?

• The patient should be asked to review events in the hours before the urticaria
appeared. What had the patient ingested (foods, beverages, candy)? Was the patient
involved in exercise or physical exertion? Was the patient exposed to extremes of
temperature or stung by an insect? The answers may reveal clues to allergic or
physical causes of urticaria.

• Patients should be questioned about any new medications or supplements in the

preceding days or weeks [43,44]. Were any medications taken in the hours before the
urticaria appeared?

• Inquiries should be made about recent travel (and symptoms of parasitic infection)
and sexual history. (See 'Infections' above.)

• A complete review of systems is valuable in the patient with new-onset urticaria.

Physical examination — Lesions should be visualized directly in order to make the diagnosis
with certainty, since the term "hives" is used nonspecifically by patients. If the patient has no
lesions at the time of evaluation, showing patients photographs of urticaria and asking if their
lesions look similar can be helpful, although the diagnosis will need to be confirmed at some
point in the future ( picture 2).

Individual urticarial lesions usually appear and resolve completely within 24 hours. If the
patient is unsure of the duration of the lesions, a lesion can be circled with a pen and time to
resolution noted.

Laboratory studies — Laboratory studies are typically normal in patients who lack any
history or physical findings to suggest an underlying disease process [3].

● For patients presenting with new-onset urticaria (with or without angioedema) in whom
the clinical history and physical exam do not suggest an underlying disorder or urticarial

- Page 13 of 32 -
New-onset urticaria

vasculitis, international, European, and British practice parameters state that laboratory
testing is not indicated [45-47]. American practice parameters state that a limited
evaluation "may be considered" in such patients, primarily for the purpose of detecting
underlying disorders earlier in the one-third of patients in whom urticaria will prove
persistent (ie, initial presentation of chronic urticaria) [48]. In this setting, complete
blood count with differential, urinalysis, erythrocyte sedimentation rate, and liver
function tests are suggested. However, the author's approach is to obtain these tests in
patients with persistent symptoms.

● In patients in whom a specific etiology is suspected, laboratory studies and further

evaluation should be directed at establishing or excluding that cause. (See 'Etiologies'
above.)

Tests for allergic causes — An allergic cause is possible if the clinical history reveals a
specific trigger to which the patient was exposed shortly before the onset of symptoms
(usually within one to two hours). If the history does suggest a possible allergy, serum tests
for allergen-specific immunoglobulin E (IgE) antibodies are appropriate, if commercially
available. For example, if a patient who does not normally eat seafood but did so at a special
occasion develops hives within 10 minutes of eating a crab cake, it would be reasonable to
obtain a crab-specific IgE test, particularly if there were no other new foods ingested and the
patient is avoiding seafood for fear of a repeat reaction. However, the interpretation of allergy
tests can require some expertise. A positive result is suggestive, although not diagnostic, of
allergy, and a negative result does not exclude allergy. Because of this, we suggest that
patients suspected of having an allergy be referred to an allergist/immunologist for further
evaluation when possible. Skin tests with fresh food, which should be performed by an allergy
specialist, is probably the most convenient, inexpensive, and sensitive way to detect food
hypersensitivity. (See 'Referral' below and "Overview of in vitro allergy tests".)

DIFFERENTIAL DIAGNOSIS

The conditions discussed in this section are those that may mimic various features of urticaria
[49]. The presence or absence of pruritus is a helpful clinical feature that can be used to
narrow the differential.
- Page 14 of 32 -
New-onset urticaria

Pruritic conditions — Pruritic conditions that are more likely to be confused with urticaria
are discussed here. An overview of the causes of pruritic dermatoses is found separately. (See
"Pruritus: Etiology and patient evaluation".)

● Atopic dermatitis – Atopic dermatitis is a common disorder that presents initially as

intensely pruritic erythematous patches with papules and some scaling. In children, the
face, scalp, extremities, or trunk are typically involved, while the diaper area is spared. In
older children and adults, the flexural areas (neck, antecubital fossae, and popliteal
fossae) are most commonly involved. Other sites include the face, wrists, and forearms (
picture 8). Erythematous areas of involvement last for days or weeks and have ill-
defined borders. Scaling and xerosis develop with time. (See "Atopic dermatitis (eczema):
Pathogenesis, clinical manifestations, and diagnosis".)

● Contact dermatitis – Contact dermatitis refers to any dermatitis arising from direct skin
exposure to a substance. The dermatitis may either be allergic or irritant-induced. The
latter is more common. Contact dermatitis is an erythematous, papular dermatitis, often
with areas of vesiculation ( picture 9). It is distributed in the areas of direct contact.
(See "Allergic contact dermatitis in children" and "Irritant contact dermatitis in adults"
and "Common allergens in allergic contact dermatitis".)

● Drug eruptions – Drug eruptions, also called morbilliform or exanthematous drug

eruptions, are cutaneous drug reactions that closely mimic viral exanthems but occur in
association with a medication. These dermatoses may or may not be pruritic and begin
as small macules and/or papules that become larger and confluent with time (
picture 10). The individual lesions are persistent, unlike urticaria. (See "Drug
eruptions".)

● Insect bites – Insect bites produce individual lesions that persist for days in most cases
(see "Insect and other arthropod bites"). However, the stings of some insects can cause
true urticaria as part of a systemic allergic reaction. (See 'IgE-mediated allergic reactions'
above.)

● Bullous pemphigoid – In older adults, bullous pemphigoid may start with pruritus, with
or without urticarial lesions. Blistering usually becomes evident eventually. (See "Clinical

- Page 15 of 32 -
New-onset urticaria

features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",

section on 'Clinical features of bullous pemphigoid'.)

● Erythema multiforme minor – Erythema multiforme minor is a syndrome

characterized by erythematous, iris-shaped macules and vesiculobullous lesions with a
target appearance ( picture 11). The lesions may be painful or pruritic and distributed
symmetrically on the extensor surfaces of the extremities (particularly the palms and
soles). Individual lesions last several days, unlike urticaria. There may be accompanying
fever and malaise. (See "Erythema multiforme: Pathogenesis, clinical features, and
diagnosis".)

● Plant-induced reactions – Poison ivy and poison oak can present with urticaria-like
lesions initially that evolve into vesicular lesions. (See "Poison ivy (Toxicodendron)
dermatitis".)

Nonpruritic conditions — Nonpruritic conditions that may resemble acute urticaria include
viral exanthems, the skin changes of auriculotemporal syndrome, and Sweet syndrome.

● Viral exanthems – Viral exanthems are common in children and can occur with many
different infections, including erythema infectiosum (fifth disease), Epstein-Barr virus,
enteroviruses, and measles. However, viral exanthems are generally not pruritic and
usually consist of erythematous maculopapular eruptions that persist for days. Fever is
often present. The macules are relatively fixed compared with urticarial lesions, which
continually change, with new lesions appearing as older lesions resolve. (See topic
reviews on specific infections.)

● Auriculotemporal syndrome – Auriculotemporal syndrome is a nonpruritic flushing

and/or sweating of the skin over the cheeks or jawline (the areas supplied by the
auriculotemporal nerve) that occurs transiently after eating and may be mistaken for
urticaria associated with food allergy [50]. It can be seen in children or adults and may
develop following damage to the nerve secondary to forceps delivery, viral infection,
surgery, or other local trauma. Unilateral distribution is typical, although bilateral cases
have been reported [51].

● Sweet syndrome – Sweet syndrome is an uncommon disease characterized by

- Page 16 of 32 -
New-onset urticaria

recurrent episodes of painful, long-lasting inflammatory papules and plaques associated

with fever, arthralgias, and peripheral leukocytosis ( picture 12). There may be a
history of a febrile illness one to three weeks before the onset of skin lesions in some
cases. (See "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis,
clinical manifestations, and diagnosis".)

TREATMENT

Initial treatment of new-onset urticaria (with or without angioedema) should focus on the
short-term relief of pruritus and angioedema, if present. Approximately two-thirds of cases of
new-onset urticaria will be self-limited and resolve spontaneously. The literature on
management of acute urticaria is sparse, probably because the condition is so often self-
limited [52]. The agents discussed below have mostly been evaluated in the treatment of
chronic urticaria, and in some cases, their use in acute urticaria is extrapolated from those
studies, which are presented separately. (See "Chronic spontaneous urticaria: Standard
management and patient education".)

H1 antihistamines — H1 antihistamines may be divided into older, first-generation agents

(eg, diphenhydramine, chlorpheniramine, hydroxyzine) and newer, second-generation agents
(eg, cetirizine, loratadine, fexofenadine, others). Second-generation agents are preferred for
both adults and children.

Second-generation agents — The newer, second-generation H1 antihistamines are

recommended as first-line therapy by published guidelines from both allergy and
dermatology expert panels [53,54]. These drugs are minimally sedating, are essentially free of
the anticholinergic effects that can complicate use of first-generation agents, have few
significant drug-drug interactions, and require less frequent dosing compared with first-
generation agents [55-59]. Second-generation agents can be sedating if combined with
alcohol, so this should be avoided. Interactions with food are noted below. We know of no
data demonstrating that any specific agent is more effective than another for the treatment
of acute urticaria, although a few studies in patients with chronic urticaria suggest that
cetirizine and levocetirizine may be modestly more effective than other agents. (See "Chronic
spontaneous urticaria: Standard management and patient education", section on 'Agents and
- Page 17 of 32 -
New-onset urticaria

efficacy studies'.)

Some patients require higher than standard doses (shown below in parentheses) for control
of urticarial symptoms and may experience drowsiness at these higher doses. Caution is
therefore warranted until effects upon the individual are understood. The higher doses may
have better efficacy in some adults, although this has not been conclusively demonstrated.
Studies of higher-dose antihistamines for chronic urticaria are reviewed separately. (See
"Chronic spontaneous urticaria: Standard management and patient education", section on
'H1 antihistamines'.)

Treatment with H1 antihistamines results in clearance of the lesions in some patients, but in
others, treatment may only achieve flattening of the lesions and reduction in pruritus, with
persistence of erythematous macules. Patients in the latter group can begin to reduce
medications after the erythematous lesions clear.

Second-generation H1 antihistamines include the following:

● Cetirizine – Cetirizine demonstrates a rapid onset of action and some mast cell-
stabilizing activity. It can be mildly sedating, in a dose-dependent manner, although less
so than first-generation agents. It is available in both intravenous (in some countries)
and oral formulations, and the dosing is similar for either route of administration.
Intravenous doses should be administered over one to two minutes. The standard oral
or intravenous dose of 10 mg once daily is appropriate for adults and children aged 12
years and older (and may be increased to 10 mg twice daily in adults if needed).

Children six years of age and older can receive 5 mg or 10 mg. The usual dose for
children aged two to five years is 5 mg once daily. Smaller children aged six months to
two years may be given 2.5 mg once daily (can be increased to 2.5 mg twice daily in
children one year and older if needed). The maintenance dose for patients with
significant renal and/or hepatic insufficiency should be reduced by one-half.

● Levocetirizine – Levocetirizine is an active enantiomer of cetirizine that produces effects

equivalent to cetirizine at about one-half of the dose. For adults and children 12 years
and older, the standard dose is 5 mg once daily in the evening (or up to 5 mg twice daily
in adults if needed) or 2.5 mg once daily in the evening for children aged 6 to 11 years.
- Page 18 of 32 -
New-onset urticaria

Levocetirizine is unlikely to be effective as an alternative for patients who did not have
an adequate response to cetirizine, and its sedative effects are similar to those of other
second-generation antihistamines [60]. Dose reductions are necessary in renal
insufficiency.

● Loratadine – Loratadine is a long-acting, selective H1 antihistamine. The standard dose

is 10 mg once daily for ages six years and older, which is minimally sedating. It can be
increased up to 10 mg twice daily in adults if needed. For children aged two to five years,
the usual dose is 5 mg once daily. For patients with significant renal and/or hepatic
insufficiency, the usual dose is administered every other day.

● Desloratadine – Desloratadine is the major active metabolite of loratadine and

produces effects equivalent to loratadine at about one-half the dose. For adults and
children 12 years and older, the standard dose is 5 mg once daily (or up to 5 mg twice
daily in adults if needed).

For children aged 6 to 11 years, the dose is 2.5 mg once daily, and for those aged 1 to 5
years, the dose is 1.25 mg once daily. A lower dose of 1 mg once daily is approved in the
United States for small children aged 6 months to 1 year. For patients with significant
renal and/or hepatic insufficiency, the usual dose is administered every other day.

● Fexofenadine – Fexofenadine is minimally sedating. The suggested dose is 180 mg daily

for ages 12 years and older (or up to twice daily in adults if needed) or 30 mg twice daily
for children aged 2 to 11 years. A lower dose of 15 mg twice daily is approved in the
United States for small children aged six months to two years. For patients with
significant renal insufficiency, the adult dose should be reduced to 60 mg once daily. It is
best taken without food and specifically not with fruit juices.

There are additional nonsedating antihistamines that are available in many countries,
although not in the United States:

● Ebastine – Ebastine is a nonsedating antihistamine that is licensed for use in children

older than 12 years of age and adults. The usual dose is 10 mg daily, but it can be
doubled to 20 mg daily if needed, although not in patients with liver insufficiency. One
study of patients with acute urticaria found that 20 mg of ebastine was similar in efficacy
- Page 19 of 32 -
New-onset urticaria

to 5 mg of levocetirizine and caused fewer adverse effects [61].

● Bilastine – Bilastine is a nonsedating antihistamine with efficacy similar to cetirizine and

higher than that of fexofenadine [62]. The initial dose is 20 mg daily for children older
than 12 years of age and adults. Bioavailability is reduced approximately 30 percent by
grapefruit juice, ketoconazole, or erythromycin, and it should not be taken with food.
The drug minimally crosses the blood-brain barrier (because it is a zwitterion), does not
cause somnolence, and is not affected by alcoholic beverages [63].

● Rupatadine – Rupatadine antagonizes both histamine and platelet-activating factor

(PAF) receptors [64]. It is licensed at a dose of 10 mg daily for patients older than 12
years of age, although it is safe in patients older than 2 years of age [65]. As is the case
for bilastine, the drug should not be taken with grapefruit juice, ketoconazole, or
erythromycin, but (unlike bilastine) it is not affected by food.

First-generation agents — The first-generation antihistamines include diphenhydramine,

chlorpheniramine, hydroxyzine, and others [66]. These agents are lipophilic and readily cross
the blood-brain barrier, causing sedating and anticholinergic side effects that may be dose-
limiting in some patients. Significant sedation and impairment of performance (eg, fine motor
skills, driving skills, and reaction times) occur in more than 20 percent of patients [67].
Anticholinergic side effects include dry mouth, diplopia, blurred vision, urinary retention, or
vaginal dryness. Patients should be warned specifically about these adverse effects. Despite
these adverse effects, patients at low risk of complications (eg, young, healthy patients) may
find a sedating H1 antihistamine at bedtime helpful, especially when combined with a
nonsedating H1 antihistamine during the day.

Some first-generation H1 antihistamines are available in parenteral preparations for use in

patients in whom a more rapid onset of action is desired, such as those who have presented
to the emergency department. Parenteral dosing of the first-generation agents is:

● Diphenhydramine – The dose in adults is 25 to 50 mg given by slow intravenous (IV)

administration or intramuscular (IM) injection every four to six hours as needed.
Children may receive 0.5 to 1.25 mg/kg (up to 50 mg per dose) IV/IM every six hours as
needed.

- Page 20 of 32 -
New-onset urticaria
● Hydroxyzine – The dose in adults is 25 to 50 mg deep IM administration in adults every
six hours as needed. Do not administer intravenously. Children may receive 0.5 to 1
mg/kg (up to 50 mg per dose) IM every six hours as needed.

Pregnant and lactating patients — Pregnant patients may be treated initially with
loratadine (10 mg once daily) or cetirizine (10 mg once daily). There are reassuring human
data for each of these drugs in a large number of pregnant patients [68]. The first-generation
agent chlorpheniramine, 4 mg orally every four to six hours, may also be safely used in
pregnancy [69,70]. Safety issues surrounding the use of antihistamines in pregnancy are
reviewed separately. (See "Recognition and management of allergic disease during
pregnancy", section on 'Oral antihistamines'.)

Lactating patients may be treated with either cetirizine or loratadine (both are dosed at 10 mg
once daily), which are minimally excreted in breast milk and should not cause sedation or
poor feeding in the infant. (See "Pharmacotherapy of allergic rhinitis", section on
'Breastfeeding'.)

H2 antihistamines — There are very few data examining the use of H2 antihistamines for
acute urticaria, but the practice is supported by one randomized trial of 91 adults presenting
to an emergency department with acute allergic reactions [71]. Subjects received 50 mg IV
diphenhydramine with either placebo or 50 mg IV ranitidine. At two hours, the number of
patients in whom urticaria had resolved was statistically greater in the ranitidine group
compared with the placebo group (25 of 29 and 13 of 24, respectively). Options for H2
antihistamines include nizatidine, famotidine, ranitidine (no longer available in the US), and
cimetidine, although caution should be used with cimetidine, since it can increase levels of
other drugs. (See "Antiulcer medications: Mechanism of action, pharmacology, and side
effects".)

Studies of the use of H2 antihistamines in chronic urticaria are conflicting and are reviewed
elsewhere [72-74]. (See "Chronic spontaneous urticaria: Standard management and patient
education", section on 'H2 antihistamines'.)

Glucocorticoids — Glucocorticoids do not appear to be necessary for isolated urticaria.

However, a brief course (ie, usually a week or less) of systemic glucocorticoids may be added

- Page 21 of 32 -
New-onset urticaria

to antihistamine therapy for patients with prominent angioedema or if symptoms persist

beyond a few days. Glucocorticoids do not inhibit mast cell degranulation but may act by
suppressing a variety of contributing inflammatory mechanisms.

A small number of trials have examined the utility of glucocorticoids in the management of
acute urticaria [75-77]. In the largest study, the addition of prednisone to levocetirizine did
not speed resolution of acute urticaria. In this randomized trial, 100 adults presenting to the
emergency department with urticaria of ≤24 hours duration without angioedema,
anaphylaxis, or fever, were treated with the H1 antihistamine levocetirizine (5 mg once daily
for five days) plus either placebo or prednisone (40 mg once daily for four days) and followed
by phone for several days [77]. The primary endpoint was complete relief of itching two days
after the start of therapy, and secondary endpoints included resolution of skin lesions,
relapses, and adverse events. Most subjects had resolution of itch by day 2, with a slightly
lower percentage itch-free in the prednisone group (79 versus 67 percent). Similarly, by day 2,
skin lesions had resolved entirely in 78 and 70 percent of those in the placebo and prednisone
groups, respectively. Thus, the addition of prednisone to levocetirizine did not speed
resolution of acute urticaria. Between one-quarter and one-third of patients experienced
relapse in both groups, generally within the first few days of therapy. Another smaller
randomized trial found that glucocorticoids were helpful when added to antihistamines,
although the antihistamine regimen used in that study (hydroxyzine 25 mg orally every four
to eight hours) may have been more difficult to adhere to [75].

The optimal agent and dose have not been determined for acute urticaria, but we typically
administer:

● In adults – Prednisone 30 to 60 mg daily, with tapering of the dose over five to seven
days
● In children – Prednisolone 0.5 to 1 mg/kg/day (maximum 60 mg daily), with tapering of
the dose over five to seven days

Antihistamine therapy should be continued during and after the course of glucocorticoids
because some patients experience an exacerbation as the glucocorticoids are tapered or
discontinued. If symptoms do not recur over several days after stopping glucocorticoids, then
antihistamines can be discontinued also. For patients whose symptoms recur when
- Page 22 of 32 -
New-onset urticaria

medications are discontinued, antihistamines should be reinstituted and used at the lowest
effective dose. Repeated courses of glucocorticoids should be avoided, as the risks of adverse
effects outweigh the benefit for most patients (see 'Referral' below). The decision of
prescribing gastrointestinal prophylaxis (eg, a proton pump inhibitor) during a systemic
corticosteroid treatment depends essentially on the duration of therapy (that in this case
should be as brief as possible) and the specific conditions of the patient (eg, prior chronic
gastritis, gastric ulcers).

REFERRAL

Patients who are suspected of having an allergic etiology causing new-onset urticaria, such as
a food or medication allergy, should be referred to an allergy specialist who will evaluated for
possible causes and equip the patient with epinephrine for self-injection when indicated.
These issues are discussed in detail separately. (See "Anaphylaxis: Emergency treatment",
section on 'Discharge care'.)

PROGNOSIS

It should be explained to patients that about one-third of cases of new-onset urticaria will
prove persistent and that if they continue to have ongoing symptoms after several weeks,
they should seek re-evaluation in a primary care setting. Patients with difficult-to-control
symptoms may also be referred to a dermatology or allergy specialist.

SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Urticaria and
angioedema (excluding hereditary angioedema)".)

INFORMATION FOR PATIENTS

- Page 23 of 32 -
New-onset urticaria

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the
Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th
grade reading level, and they answer the four or five key questions a patient might have
about a given condition. These articles are best for patients who want a general overview and
who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are
longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th
grade reading level and are best for patients who want in-depth information and are
comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to
print or e-mail these topics to your patients. (You can also locate patient education articles on
a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

● Basics topic (see "Patient education: Hives (The Basics)")

● Beyond the Basics topic (see "Patient education: Hives (urticaria) (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

● Prevalence and description – Urticaria (also called hives or wheals) affect up to 20

percent of the population at some point in their lives. Urticarial lesions are intensely
pruritic, circumscribed, raised, erythematous plaques, often with central pallor (
picture 1). Morphology and size can vary ( picture 2). Urticarial lesions typically
develop over minutes to hours and resolve in hours to a day without residual markings.
There may be accompanying angioedema, which is swelling deeper in the skin. (See
'Clinical manifestations' above and 'Epidemiology' above.)

● Acute versus chronic – Urticaria is classified as either acute or chronic. Acute urticaria is
defined as periodic outbreaks of urticarial lesions that resolve within six weeks. Urticaria
that persists beyond six weeks may represent the beginning of chronic urticaria, a
disorder that is reviewed in detail separately. (See 'Categorization of urticaria' above and
"Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and
natural history".)

- Page 24 of 32 -
New-onset urticaria
● Possible triggers for new-onset urticaria – A presumptive trigger, such as common
viral and bacterial infections, medications, food ingestion, or insect sting, can
sometimes be identified for new-onset urticaria. (See 'Etiologies' above.)

● Systemic disorders that can involve urticaria – Occasionally, urticaria may be the
presenting feature of another systemic disorder, such as urticarial vasculitis,
mastocytosis, or systemic lupus erythematous. There are specific clinical features that
should prompt an evaluation for these conditions. (See 'Systemic disorders that may
include urticaria' above.)

● Diagnosis – The diagnosis of urticaria is made clinically. A careful history should be

performed to exclude possible anaphylaxis, identify a possible trigger, and determine if
there are signs or symptoms to suggest urticarial vasculitis or an underlying systemic
disorder. If the history does not suggest a specific trigger or underlying systemic illness,
then laboratory tests are usually normal and not helpful. Some guidelines advocate
obtaining a complete blood count with differential, urinalysis, erythrocyte sedimentation
rate, and liver function tests at initial presentation, while others suggest no testing
unless symptoms persist. (See 'Evaluation and diagnosis' above.)

● Differential diagnosis – Urticarial lesions are nearly always pruritic.

• Other pruritic disorders that could be confused with urticaria include insect bites,
atopic dermatitis, contact dermatitis, morbilliform drug eruptions, bullous
pemphigoid, erythema multiforme minor, and plant-related dermatoses (eg, poison
ivy). (See 'Pruritic conditions' above.)

• Nonpruritic conditions that may resemble acute urticaria include viral exanthems,
the skin changes of auriculotemporal syndrome, and Sweet syndrome. (See
'Nonpruritic conditions' above.)

● Management – The management of new-onset urticaria depends upon severity and

associated angioedema.

• In patients with mild symptoms of new-onset urticaria, we suggest treatment with a

nonsedating H1 antihistamine alone (Grade 2B). Some patients may require higher
- Page 25 of 32 -
New-onset urticaria

than standard doses (eg, cetirizine 10 mg twice daily). In patients at low risk of
complications from anticholinergic side effects (ie, healthy adults), use of a sedating
H1 antihistamine at bedtime and a nonsedating H1 antihistamine during the day is a
reasonable alternative. (See 'H1 antihistamines' above.)

• In patients with persistent symptoms despite an H1 antihistamine or with prominent

angioedema, we suggest adding a brief course of oral glucocorticoids (Grade 2C). We
typically administer prednisone (30 to 60 mg daily) in adults or prednisolone (0.5 to 1
mg/kg/day) in children, tapered over five to seven days, while antihistamines are
continued. (See 'Glucocorticoids' above.)

● Prognosis – Two-thirds of cases of urticaria (with or without angioedema) prove to be

self-limited, resolving in days to a few weeks. Urticarial outbreaks that continue to occur
after six weeks are classified as chronic. Patients with difficult to control symptoms that
are persistent can be referred to an allergy or dermatology specialist.

ACKNOWLEDGMENT

The UpToDate editorial staff acknowledges Clifton O Bingham, III, MD, who contributed to
earlier versions of this topic review.

REFERENCES

1. Kaplan AP. Urticaria and angioedema. In: Middleton's Allergy: Principles and practice, 7th,
Adkinson NF, Bochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FER (Eds), Mosby,
St Louis, MO 2009. Vol 2, p.1063.
2. Sackesen C, Sekerel BE, Orhan F, et al. The etiology of different forms of urticaria in
childhood. Pediatr Dermatol 2004; 21:102.

3. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;
346:175.
4. Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy
specimens from patients with chronic idiopathic urticaria: comparison with the allergen-
induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109:694.
- Page 26 of 32 -
New-onset urticaria

5. Mortureux P, Léauté-Labrèze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and

early childhood: a prospective study. Arch Dermatol 1998; 134:319.

6. Plumb J, Norlin C, Young PC, Utah Pediatric Practice Based Research Network. Exposures
and outcomes of children with urticaria seen in a pediatric practice-based research
network: a case-control study. Arch Pediatr Adolesc Med 2001; 155:1017.

7. Imbalzano E, Casciaro M, Quartuccio S, et al. Association between urticaria and virus

infections: A systematic review. Allergy Asthma Proc 2016; 37:18.
8. Minciullo PL, Cascio A, Barberi G, Gangemi S. Urticaria and bacterial infections. Allergy
Asthma Proc 2014; 35:295.

9. Caubet JC, Kaiser L, Lemaître B, et al. The role of penicillin in benign skin rashes in
childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol 2011;
127:218.

10. Wu CC, Kuo HC, Yu HR, et al. Association of acute urticaria with Mycoplasma pneumoniae
infection in hospitalized children. Ann Allergy Asthma Immunol 2009; 103:134.
11. Shah KN, Honig PJ, Yan AC. "Urticaria multiforme": a case series and review of acute
annular urticarial hypersensitivity syndromes in children. Pediatrics 2007; 119:e1177.

12. Cribier B. Urticaria and hepatitis. Clin Rev Allergy Immunol 2006; 30:25.
13. Friedman D, Picard-Dahan C, Grossin M, et al. Chronic urticaria revealing an HIV infection.
Eur J Dermatol 1995; 5:40.

14. Panda M, Agarwal A, Hassanandani T. Dermatological Manifestations of COVID-19 in

Children. Indian Pediatr 2022; 59:393.
15. Polly S, Fernandez AP. Common skin signs of COVID-19 in adults: An update. Cleve Clin J
Med 2022; 89:161.
16. Tan SW, Tam YC, Pang SM. Cutaneous reactions to COVID-19 vaccines: A review. JAAD Int
2022; 7:178.

17. Di Campli C, Gasbarrini A, Nucera E, et al. Beneficial effects of Helicobacter pylori

eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43:1226.
18. Del Pozo MD, Audícana M, Diez JM, et al. Anisakis simplex, a relevant etiologic factor in
acute urticaria. Allergy 1997; 52:576.

- Page 27 of 32 -
New-onset urticaria

19. Duperrex O, Tommasini F, Muller YD. Incidence of Chronic Spontaneous Urticaria

Following Receipt of the COVID-19 Vaccine Booster in Switzerland. JAMA Netw Open
2023; 6:e2254298.
20. Sussman GL, Beezhold DH. Allergy to latex rubber. Ann Intern Med 1995; 122:43.

21. Wang J, Sampson HA. Food allergy. J Clin Invest 2011; 121:827.
22. Asero R, Antonicelli L, Arena A, et al. EpidemAAITO: features of food allergy in Italian
adults attending allergy clinics: a multi-centre study. Clin Exp Allergy 2009; 39:547.

23. Bourrain JL. Occupational contact urticaria. Clin Rev Allergy Immunol 2006; 30:39.
24. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the
definition, classification, diagnosis and management of urticaria. Allergy 2018; 73:1393.

25. Robledo T, Cimarra M, Agustin P, Martinez-Cocera C. Adverse reaction to

dextromethorphan. Allergy 2004; 59:890.
26. Anderson BE, Miller CJ, Adams DR. Stinging nettle dermatitis. Am J Contact Dermat 2003;
14:44.
27. Cummings AJ, Olsen M. Mechanism of action of stinging nettles. Wilderness Environ Med
2011; 22:136.

28. Uslu S, Bulbul A, Diler B, et al. Urticaria due to Urtica dioica in a neonate. Eur J Pediatr
2011; 170:401.
29. Oliver F, Amon EU, Breathnach A, et al. Contact urticaria due to the common stinging
nettle (Urtica dioica)--histological, ultrastructural and pharmacological studies. Clin Exp
Dermatol 1991; 16:1.
30. Poole JA, Rosenwasser LJ. Chronic idiopathic urticaria exacerbated with progesterone
therapy treated with novel desensitization protocol. J Allergy Clin Immunol 2004; 114:456.

31. Shank JJ, Olney SC, Lin FL, McNamara MF. Recurrent postpartum anaphylaxis with breast-
feeding. Obstet Gynecol 2009; 114:415.
32. Bandino JP, Thoppil J, Kennedy JS, Hivnor CM. Iatrogenic autoimmune progesterone
dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor
prevention. Cutis 2011; 88:241.
33. Le K, Wood G. A case of autoimmune progesterone dermatitis diagnosed by
- Page 28 of 32 -
New-onset urticaria

progesterone pessary. Australas J Dermatol 2011; 52:139.

34. Bernstein IL, Bernstein DI, Lummus ZL, Bernstein JA. A case of progesterone-induced
anaphylaxis, cyclic urticaria/angioedema, and autoimmune dermatitis. J Womens Health
(Larchmt) 2011; 20:643.
35. Prieto-Garcia A, Sloane DE, Gargiulo AR, et al. Autoimmune progesterone dermatitis:
clinical presentation and management with progesterone desensitization for successful
in vitro fertilization. Fertil Steril 2011; 95:1121.e9.
36. Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity:
associations found in a large population study. J Allergy Clin Immunol 2012; 129:1307.

37. Charlesworth EN. The spectrum of urticaria: All that urticates may not be urticaria.
Immunol Allergy Clin North Am 1995; 15:641.
38. Beltrani VS. Urticaria and angioedema. Dermatol Clin 1996; 14:171.

39. Charlesworth EN. Urticaria and angioedema: a clinical spectrum. Ann Allergy Asthma
Immunol 1996; 76:484.
40. Beltrani VS. Urticaria: reassessed. Allergy Asthma Proc 2004; 25:143.

41. Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis
Clin North Am 1994; 20:195.
42. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with
thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84:66.

43. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997;
278:1895.
44. Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy
Asthma Immunol 2002; 89:542.
45. Grattan CE, Humphreys F, British Association of Dermatologists Therapy Guidelines and
Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults
and children. Br J Dermatol 2007; 157:1116.

46. Zuberbier T. A Summary of the New International EAACI/GA(2)LEN/EDF/WAO Guidelines

in Urticaria. World Allergy Organ J 2012; 5:S1.

47. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline:

- Page 29 of 32 -
New-onset urticaria

definition, classification and diagnosis of urticaria. Allergy 2009; 64:1417.

48. Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a
practice parameter part I: acute urticaria/angioedema part II: chronic
urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma
Immunol 2000; 85:521.

49. Weldon D. When your patients are itching to see you: not all hives are urticaria. Allergy
Asthma Proc 2005; 26:1.
50. Sicherer SH, Sampson HA. Auriculotemporal syndrome: a masquerader of food allergy. J
Allergy Clin Immunol 1996; 97:851.

51. Karunananthan CG, Kim HL, Kim JH. An unusual case of bilateral auriculotemporal
syndrome presenting to an allergist. Ann Allergy Asthma Immunol 2002; 89:104.
52. Beno SM, Nadel FM, Alessandrini EA. A survey of emergency department management of
acute urticaria in children. Pediatr Emerg Care 2007; 23:862.
53. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline:
management of urticaria. Allergy 2009; 64:1427.

54. Grattan C, Powell S, Humphreys F, British Association of Dermatologists. Management

and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144:708.
55. Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin
Immunol 2001; 107:751.

56. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and
symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled
study. Int J Dermatol 2001; 40:72.

57. Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and

desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann
Allergy Asthma Immunol 2004; 92:635.
58. Simons FE, Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of
levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy
Immunol 2007; 18:535.
59. Garg G, Thami GP. Comparative efficacy of cetirizine and levocetirizine in chronic

- Page 30 of 32 -
New-onset urticaria

idiopathic urticaria. J Dermatolog Treat 2007; 18:23.

60. Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, Chitsuthipakorn W. Sedative

Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized
Controlled Studies. Drugs 2017; 77:175.
61. Goyal V, Gupta A, Gupta O, et al. Comparative Efficacy and Safety of Ebastine 20 mg,
Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. J Clin Diagn Res 2017;
11:WC06.
62. Jáuregui I, Bartra J, del Cuvillo A, et al. Bilastine and quality of life. J Investig Allergol Clin
Immunol 2011; 21 Suppl 3:16.

63. Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of
allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011; 10:779.
64. González-Núñez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic
rhinitis and urticaria. Expert Opin Drug Saf 2016; 15:1439.
65. Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic
spontaneous urticaria in children aged 2-11 years. Pediatr Allergy Immunol 2016; 27:55.

66. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004;
114:465.
67. Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions.
Arch Intern Med 1997; 157:494.

68. Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern
Fetal Neonatal Med 2002; 11:146.
69. Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997;
78:157.
70. Schatz M, Zeiger RS. Asthma and allergy in pregnancy. Clin Perinatol 1997; 24:407.
71. Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic
syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med
2000; 36:462.
72. Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria.
Cochrane Database Syst Rev 2012; :CD008596.

- Page 31 of 32 -
New-onset urticaria

73. Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine
therapy in chronic urticaria. Arch Dermatol 1981; 117:404.
74. Guevara-Gutierrez E, Bonilla-Lopez S, Hernández-Arana S, Tlacuilo-Parra A. Safety and
efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: Double-blind
randomized placebo-controlled study. J Dermatolog Treat 2015; 26:548.
75. Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of
prednisone. Ann Emerg Med 1995; 26:547.

76. Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: clinical aspects and
therapeutic responsiveness. Acta Derm Venereol 1996; 76:295.
77. Barniol C, Dehours E, Mallet J, et al. Levocetirizine and Prednisone Are Not Superior to
Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind
Clinical Trial. Ann Emerg Med 2017.

Topic 8101 Version 41.0

© 2023 UpToDate, Inc. All rights reserved.

- Page 32 of 32 -